{
    "clinical_study": {
        "@rank": "99296", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A (ABBV-399)", 
                "arm_group_type": "Experimental", 
                "description": "ABBV-399 will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABBV-399."
            }, 
            {
                "arm_group_label": "Cohort B (ABBV 399 plus Erlotinib)", 
                "arm_group_type": "Experimental", 
                "description": "ABBV-399 to be evaluated with Erlotinib."
            }, 
            {
                "arm_group_label": "Cohort C (ABBV-399 plus Cetuximub)", 
                "arm_group_type": "Experimental", 
                "description": "ABBV-399 to be evaluated with Cetuximub."
            }, 
            {
                "arm_group_label": "Cohort D (ABBV-399 plus Bevacizumab)", 
                "arm_group_type": "Experimental", 
                "description": "ABBV-399 to be evaluated with Bevacizumab."
            }, 
            {
                "arm_group_label": "Cohort E (ABBV-399 plus Carboplatin)", 
                "arm_group_type": "Experimental", 
                "description": "ABBV-399 to be evaluated with Carboplatin."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and\n      preliminary efficacy of ABBV-399 in subjects with advanced solid tumors. The early clinical\n      development plan for ABBV-399 is based on the activity demonstrated in preclinical models."
        }, 
        "brief_title": "A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumor", 
            "Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject must have advanced solid tumor that is not amenable to surgical resection or\n             other approved therapeutic options that have demonstrated clinical benefit.\n\n          2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to\n             2.\n\n          3. Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors\n             (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:\n\n             - Subject with non-evaluable or non-measurable cancer are eligible if they have a\n             confirmed increase in tumor antigens \u2265 2 \u00d7 upper limit of normal (ULN).\n\n          4. Subject has one of the following tumor tissues confirmed available for analyses:\n\n               -  Archived diagnostic formalin-fixed paraffin embedded (FFPE) or\n\n               -  Biopsy collected prior to study drug administration (FFPE).\n\n          5. Subject has adequate bone marrow, renal, and hepatic function.\n\n          6. Women of childbearing potential must have a negative serum pregnancy test within 14\n             days prior to initiation of treatment.\n\n          7. Subjects in the combination therapy arms must be eligible to receive erlotinib,\n             cetuximab, bevacizumab or carboplatin per most current prescribing information, or at\n             the discretion of the Investigator.\n\n        Exclusion Criteria:\n\n          1. Subject has received anticancer therapy including chemotherapy, radiation therapy,\n             immunotherapy, biologic, or any investigational therapy within a period of 21 days or\n             herbal therapy within 7 days prior to the first dose of ABBV-399.\n\n          2. Subject has known uncontrolled metastases to the central nervous system (CNS).\n             Subjects with brain metastases are eligible provided they have shown clinical and\n             radiographic stable disease for at least 4 weeks after definitive therapy and have\n             not used steroids for at least 4 weeks prior to first dose of ABBV-399.\n\n          3. Subject has unresolved adverse events >= Grade 2 from prior anticancer therapy,\n             except for alopecia or anemia.\n\n          4. Subject has had major surgery within 21 days prior to the first dose of ABBV-399.\n\n          5. Subject has a clinically significant uncontrolled condition(s).\n\n          6. Subject has history of major immunologic reaction to any Immunoglobulin G (IgG)\n             containing agent.\n\n          7. Subjects enrolled on the combination therapy phase must satisfy the above exclusion\n             criteria and also the following:\n\n               -  Subjects may not receive ABBV-399 in combination with erlotinib, cetuximab,\n                  bevacizumab or carboplatin if they have any medical condition which in the\n                  opinion of the Investigator places the subject at an unacceptably high risk for\n                  toxicities from the combination.\n\n                  i. Subjects may not receive cetuximab if they have K-ras mutation. ii. Subjects\n                  may not receive bevacizumab if they have squamous Non-small-cell lung carcinoma\n                  (NSCLC)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "154", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099058", 
            "org_study_id": "M14-237"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A (ABBV-399)", 
                    "Cohort B (ABBV 399 plus Erlotinib)", 
                    "Cohort C (ABBV-399 plus Cetuximub)", 
                    "Cohort D (ABBV-399 plus Bevacizumab)", 
                    "Cohort E (ABBV-399 plus Carboplatin)"
                ], 
                "description": "It is administered by infusion in 21-day dosing cycles.", 
                "intervention_name": "ABBV-399", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort B (ABBV 399 plus Erlotinib)", 
                "description": "It is administered orally everyday.", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort C (ABBV-399 plus Cetuximub)", 
                "description": "It is an intravenous infusion administered every 7 days.", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort D (ABBV-399 plus Bevacizumab)", 
                "description": "It is an intravenous infusion administered every 21 days.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort E (ABBV-399 plus Carboplatin)", 
                "description": "It is an intravenous infusion administered every 21 days.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Cetuximab", 
                "Carboplatin", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Advanced Solid Tumor", 
            "Neoplasm", 
            "Cancer"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Site Reference ID/Investigator# 123761"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123761", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Site Reference ID/Investigator# 123763"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123763", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "brage.garofalo@abbvie.com", 
            "last_name": "Brage  Garofalo, MA", 
            "phone": "650-454-2023"
        }, 
        "overall_contact_backup": {
            "email": "lan.wang@abbvie.com", 
            "last_name": "Lan   Wang", 
            "phone": "650-454-2024"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Louie  Naumovski, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit.", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Terminal elimination half life", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "AUC (0-t) = Area under the serum concentration versus time curve form time zero (pre-dose) to the time of the last measurable concentration.", 
                "measure": "Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099058"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ORR is defined as the proportion of the subjects who have a complete response (CR) or partial response (PR).", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "PFS is defined as the time from the first dose date of ABBV-399 to either disease progression or death, whichever occurs first.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "DOR is defined as the time from the subject's initial CR or PR to the time of disease progression.", 
                "measure": "Duration of overall response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}